Top

Published in:

Open Access 01-10-2021 | Atopic Dermatitis | Review

The Unmet Needs in Atopic Dermatitis Control in Latin America: A Multidisciplinary Expert Perspective

Authors: Jorge Sanchez, Ivan Cherrez-Ojeda, Cesar Galvan, Elizabeth Garcia, Natalia Hernández-Mantilla, Angela Londoño Garcia, Elizabeth McElwee, Mariana Rico Restrepo, Enrique Rivas, Benjamin Hidalgo

Published in: Dermatology and Therapy | Issue 5/2021

Abstract

Introduction

Adoption of control tools for atopic dermatitis (AD) in Latin America (LA) is currently very limited. Clinical assessment tools represent a practical method to measure the impact of treatment on disease activity and on the quality of life of patients. However, the use of these tools in the LA clinical practice setting is limited.

Methods

A selected panel of Latin American experts in fields related to atopic dermatitis were provided with a series of relevant questions to address prior to the multi-day conference. Within this conference, each narrative was discussed and edited by the entire group, through numerous drafts and rounds of discussion, until a consensus was achieved.

Results

The panel proposes specific and realistic recommendations for implementing control tools for AD care in LA. In creating these recommendations, the authors strove to address all barriers to the widespread use of these tools.

Conclusion

This article includes a narrative analysis of barriers to AD control in LA and provides necessary recommendations to integrate and increase the use of validated AD control assessment tools throughout the region.

Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–49. https://doi.org/10.1016/j.jaci.2016.06.010.CrossRefPubMed

Sociedad Argentina de Dermatología. Consenso Nacional de Dermatitis Atópica. Sociedad Argentina de Dermatología. 2004. http://www.dermatolarg.org.ar/index.php/dermatolarg/article/viewFile/379/189

Boothe WD, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21–37. https://doi.org/10.1007/978-3-319-64804-0_3.CrossRef

Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26–30. https://doi.org/10.1016/j.jid.2016.07.012.CrossRefPubMed

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Prim. 2018;4(1):1. https://doi.org/10.1038/s41572-018-0001-z.CrossRefPubMed

Silverberg J. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(33):283–9. https://doi.org/10.1016/j.det.2017.02.002.CrossRefPubMed

Sánchez J, Páez B, Macías A, Olmos C, De Falco A. Atopic dermatitis guideline. Position paper from the Latin America Society of Allergy, Asthma and Immunology. Rev Alerg Mex. 2014;61(3):178–211 (PMID: 25177854).PubMed

Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–60. https://doi.org/10.1016/S0140-6736(20)31286-1.CrossRefPubMed

Weng Y, Thyssen J, Silverberg J. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80:390–401. https://doi.org/10.1016/j.jaad.2018.09.035.CrossRef

10.

Sánchez J, Sánchez A, Cardona R. Critical review of ISAAC results for atopic dermatitis in tropical cities. Rev Alerg Mex. 2018;65(4):389–99. https://doi.org/10.29262/ram.v63i4.238.CrossRefPubMed

11.

Garg N, Silverberg J. Epidemiology of childhood atopic dermatitis. Clin Dermatol. 2015;33:281–8. https://doi.org/10.1016/j.clindermatol.2014.12.004.e.CrossRefPubMed

12.

Solé D, Mallol J, Wandalsen GF, Aguirre V, Latin American ISAAC Phase 3 Study Group. Prevalence of Symptoms of Eczema in Latin America: Results of the International Study of Asthma and Allergies in Childhood (ISAAC) Phase 3. J Investig Allergol Clin Immunol. 2010;20(4):311–23.PubMed

13.

Sánchez J, Sánchez A, Cardona R. Particular characteristics of atopic eczema in tropical environments. The Tropical Environment Control for Chronic Eczema and Molecular Assessment (TECCEMA) cohort study. An Bras Dermatol. 2017;92(2):177–83. https://doi.org/10.1590/abd1806-4841.20175140.CrossRefPubMedPubMedCentral

14.

Herrera-Sánchez DA, Hernández-Ojeda M, Vivas-Rosales IJ. Estudio epidemiológico sobre dermatitis atópica en México [Epidemiological study on atopic dermatitis in Mexico]. Rev Alerg Mex. 2019;66(2):192–204. https://doi.org/10.29262/ram.v66i2.591.CrossRefPubMed

15.

Dennis RJ, Caraballo L, García E, Rojas MX, Rondon MA, Pérez A, et al. Prevalence of asthma and other allergic conditions in Colombia 2009–2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17. https://doi.org/10.1186/1471-2466-12-17.CrossRefPubMedPubMedCentral

16.

Moreno-lópez S, Pérez-herrera LC, Peñaranda D, Hernández D, García E, Peñaranda A. Prevalence and associated factors of allergic diseases in school children and adolescents aged 6–7 and 13–14 years from two rural areas in Colombia. Allergol Immunopathol (Madr). 2021;49(116):2–9. https://doi.org/10.15586/aei.v49i2.183.CrossRef

17.

Cooper PJ, Vaca M, Rodriguez A, Chico ME, Santos DN, Rodrigues LC, et al. Hygiene, atopy and wheeze–eczema–rhinitis symptoms in schoolchildren from urban and rural Ecuador. Thorax. 2014. https://doi.org/10.1136/thoraxjnl-2013-203818.CrossRefPubMed

18.

Solis-Soto MT, Patiño A, Nowak D, Radon K. Association between environmental factors and current asthma, rhinoconjunctivitis and eczema symptoms in school-aged children from Oropeza Province–Bolivia: a cross-sectional study. Environ Heal. 2013;12(1):95. https://doi.org/10.1186/1476-069X-12-95.CrossRef

19.

Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526-1532.e7. https://doi.org/10.1016/j.jaad.2018.05.1241.CrossRefPubMed

20.

Sánchez J, Sánchez MR, Macías-Weinmann A, Barreto B, Ensina LF, Uriarte-Obando SA, et al. Systematic review about 10 interventions in dermatitis. A document from the Latin American Society of Allergy, Asthma, and Immunology. Rev Alerg Mex. 2019;66(4):426–55. https://doi.org/10.29262/ram.v66i4.636.CrossRefPubMed

21.

Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma). Guía de práctica clínica (GPC) para el diagnóstico y tratamiento de la dermatitis atópica en Colombia [Clinical practice guidelines (CPG) for the diagnosis and treatment of atopic dermatitis in Colombia]. Rev Asoc Colomb Dermatol Cir Dermatol. 2020.

22.

Rincón-Pérez C, Larenas-Linnemann D, Figueroa-Morales MA, Luna-Pech J, García-Hidalgo L, Macías-Weinmann A, et al. Consenso mexicano para el diagnóstico y tratamiento de la dermatitis atópica en adolescentes y adultos [Mexican consensus on the diagnosis and treatment of atopic dermatitis in adolescents and adults]. Rev Alerg Mex. 2018;65(Suppl 2):s8–88. https://doi.org/10.29262/ram.v65i6.526.CrossRefPubMed

23.

Comité Nacional de Dermatología. Consenso Nacional de Dermatitis Atópica 2013: resumen ejecutivo [Atopic dermatitis: national consensus 2013]. Arch Argent Pediatr. 2014;112(3):293–4. https://doi.org/10.5546/aap.2014.293.CrossRef

24.

Aoki V, Lorenzini D, Orfali RL, Zaniboni MC, de Oliveira ZNP, Rivitti-Machado MC, et al. Consensus on the therapeutic management of atopic dermatitis-Brazilian Society of Dermatology. An Bras Dermatol. 2019. https://doi.org/10.1590/abd1806-4841.2019940210.CrossRefPubMedPubMedCentral

25.

Antunes AA, Solé D, Carvalho VO, Bau AEK, Kuschnir FC, Mallozi MC, et al. Guia prático de atualização em dermatite atópica-parte I: etiopatogenia, clínica e diagnóstico. Posicionamento conjunto da Associação Brasileira de Alergia e Imunologia e da Sociedade Brasileira de Pediatria [Updated practical guide on atopic dermatitis-part I: etiopathogenesis, clinical features, and diagnosis. Joint position paper of the Brazilian Association of Allergy and Immunology and the Brazilian Society of Pediatrics]. Arq Asma Alerg Imunol. 2017;1(2):131–56. https://doi.org/10.5935/2526-5393.20170019.CrossRef

26.

Thomas J, Peterson GM, Walton SF, Carson CF, Naunton M, Baby KE. Scabies: an ancient global disease with a need for new therapies. BMC Infect Dis. 2015;15:250. https://doi.org/10.1186/s12879-015-0983-z.CrossRefPubMedPubMedCentral

27.

Heukelbach J, Wilcke T, Winter B, Feldmeier H. Epidemiology and morbidity of scabies and pediculosis capitis in resource-poor communities in Brazil. Br J Dermatol. 2005;153(1):150–6. https://doi.org/10.1111/j.1365-2133.2005.06591.x.CrossRefPubMed

28.

Zhang W, Zhang Y, Luo L, Huang W, Shen X, Dong X, et al. Trends in prevalence and incidence of scabies from 1990 to 2017: findings from the global Burden of disease study 2017. Emerg Microbes Infect. 2020;9(1):813–6. https://doi.org/10.1080/22221751.2020.1754136.CrossRefPubMedPubMedCentral

29.

Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91–101. https://doi.org/10.1016/j.jaip.2019.06.044.CrossRefPubMed

30.

Karthikeyan K, Thappa DM, Jeevankumar B. Pattern of pediatric dermatoses in a referral center in South India. Indian Pediatr. 2004;41(4):373–7 (PMID: 15123866).PubMed

31.

Bechelli LM, Haddad N, Pimenta WP, Pagnano PM, Melchior E Jr, Fregnan RC, et al. Epidemiological survey of skin diseases in schoolchildren living in the Purus Valley (Acre State, Amazonia, Brazil). Dermatologica. 1981;163(1):78–93. https://doi.org/10.1159/000250144.CrossRefPubMed

32.

Inanir I, Sahin MT, Gunduz K, Dinc G, Turel A, Ozturkcan S. Prevalence of skin conditions in primary school children in Turkey: differences based on socioeconomic factors. Pediatr Dermatol. 2002;19(4):307–11. https://doi.org/10.1046/j.1525-1470.2002.00087.x.CrossRefPubMed

33.

Bravo FG. Infective dermatitis: a purely cutaneous manifestation of HTLV-1 infection. Semin Diagn Pathol. 2019. https://doi.org/10.1053/j.semdp.2019.04.002.CrossRefPubMed

34.

Peled A, Sarig O, Sun G, Samuelov L, Ma CA, Zhang Y, et al. Loss-of-function mutations in caspase recruitment domain-containing protein 14 (CARD14) are associated with a severe variant of atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):173-181.e10. https://doi.org/10.1016/j.jaci.2018.09.002.CrossRefPubMed

35.

Mellett M. Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease. Cell Immunol. 2020;354: 104147. https://doi.org/10.1016/j.cellimm.2020.104147.CrossRefPubMed

36.

Caraballo L, Zakzuk J, Lee BW, Acevedo N, Soh JY, Sánchez-Borges M, et al. Particularities of allergy in the Tropics. World Allergy Organ J. 2016. https://doi.org/10.1186/s40413-016-0110-7.CrossRefPubMedPubMedCentral

37.

Lozano AM, López JF, Zakzuk J, García E. Papular urticaria: a review of causal agents in Colombia. Biomedica. 2016;36:632–45. https://doi.org/10.7705/biomedica.v36i4.3258.CrossRefPubMed

38.

Chalmers JR, Thomas KS, Apfelbacher C, Williams HC, Prinsen CA, Spuls PI, et al. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2018;178(5):e332–41. https://doi.org/10.1111/bjd.16543.CrossRefPubMed

39.

de Bruin-Weller M, Simpson EL, Cork M, Chen Z, Msihid J, Taniou C, et al. Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. J Am Acad Dermatol. 2020;83(5):1499–501. https://doi.org/10.1016/j.jaad.2020.05.142.CrossRefPubMed

40.

Genuneit J, Braig S, Brandt S, Wabitsch M, Florath I, Brenner H, et al. Infant atopic eczema and subsequent attention-deficit/hyperactivity disorder–a prospective birth cohort study. Pediatr Allergy Immunol. 2014;25(1):51–6. https://doi.org/10.1111/pai.12152.CrossRefPubMed

41.

Ivert LU, Wahlgren CF, Lindelöf B, Dal H, Bradley M, Johansson EK. Association between atopic dermatitis and autoimmune diseases: a population-based case-control study. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19624.CrossRefPubMedPubMedCentral

42.

Cheng BT, Silverberg NB, Silverberg JI. Association of childhood atopic dermatitis with atopic and nonatopic multimorbidity. Dermatitis. 2020. https://doi.org/10.1097/DER.0000000000000644.CrossRefPubMed

43.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, Parallel-Group study to evaluate dupilumab efficacy/safety in patients with uncontrolled moderate-to-severe asthma. Adv Ther. 2018;35(5):737–48. https://doi.org/10.1007/s12325-018-0702-4.CrossRefPubMedPubMedCentral

44.

Sánchez J, Toro Y, Cardona R. Clinical impact in the real life of guidelines recommendations for atopic dermatitis in a tropical population (TECCEMA cohort). Rev Alerg Mex. 2017;64(3):260–9. https://doi.org/10.29262/ram.v64i3.244.CrossRefPubMed

45.

Arruda LK, Campos Yang A, Aoki V, Fachini RJC, Cezar Pires M, Lupi O, et al. Clinical features and disease management of adult patients with atopic dermatitis receiving care at reference hospitals in Brazil: the ADAPT Study. J Investig Allergol Clin Immunol. 2021. https://doi.org/10.18176/jiaci.0478.CrossRefPubMed

46.

Urrutia-Pereira M, Solé D, Rosario NA, Neto HJC, Acosta V, Almendarez CF, et al. Sleep-related disorders in Latin-American children with atopic dermatitis: a case control study. Allergol Immunopathol (Madr). 2017;45(3):276–82. https://doi.org/10.1016/j.aller.2016.08.014.CrossRef

47.

Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong C. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22(1):10S-16S. https://doi.org/10.1177/1203475418803628.CrossRefPubMed

48.

Reich A. Reliable assessment of atopic dermatitis severity: do we need more tools? Br J Dermatol. 2021;184(1):6–7. https://doi.org/10.1111/bjd.19392.CrossRefPubMed

49.

Bożek A, Reich A. Assessment of intra- and inter-rater reliability of three methods for measuring atopic dermatitis severity: EASI, objective SCORAD, and IGA. Dermatology. 2017;233(1):16–22. https://doi.org/10.1159/000472711.CrossRefPubMed

50.

Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985–2010. PLoS ONE. 2011;6(4): e17520. https://doi.org/10.1371/journal.pone.0017520.CrossRefPubMedPubMedCentral

51.

European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31. https://doi.org/10.1159/000247298.CrossRef

52.

Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10–9. https://doi.org/10.1159/000245677.CrossRefPubMed

53.

Kim DH, Li K, Seo SJ, Jo SJ, Yim HW, Kim CM, et al. Quality of life and disease severity are correlated in patients with atopic dermatitis. J Korean Med Sci. 2012;27(11):1327–32. https://doi.org/10.3346/jkms.2012.27.11.1327.CrossRefPubMedPubMedCentral

54.

Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. https://doi.org/10.1111/j.1398-9995.2011.02719.x.CrossRefPubMed

55.

Oranje AP, Glazenburg EJ, Wolkerstorfer A, van der Waard SFB. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol. 2007;157(4):645–8. https://doi.org/10.1111/j.1365-2133.2007.08112.x.CrossRefPubMed

56.

Wolkerstorfer AA, van der Waard SFB, Glazenburg EJ, Mulder PG, Oranje AP. Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol. 1999;79(5):356–9. https://doi.org/10.1080/000155599750010256.CrossRefPubMed

57.

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Eval Group Exp Dermatol. 2001;10(1):11–8. https://doi.org/10.1034/j.1600-0625.2001.100102.x.CrossRef

58.

Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol. 2017;140(6):1708-10.e1. https://doi.org/10.1016/j.jaci.2017.04.052.CrossRefPubMedPubMedCentral

59.

Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46(4):495–504. https://doi.org/10.1067/mjd.2002.122187.CrossRefPubMed

60.

Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016;74(2):288–94. https://doi.org/10.1016/j.jaad.2015.09.062.CrossRefPubMed

61.

Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberrg JI, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839–46. https://doi.org/10.1016/j.jaad.2020.04.104.CrossRefPubMed

62.

Chopra R, Silverberg JI. Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol. 2018;36(5):606–15. https://doi.org/10.1016/j.clindermatol.2018.05.012.CrossRefPubMed

63.

Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75–91. https://doi.org/10.1111/ijd.14763.CrossRefPubMed

64.

Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12(5):445–59. https://doi.org/10.1007/s40271-019-00373-y.CrossRefPubMedPubMedCentral

65.

Lara-Corrales I, Bergman JN, Landells I, Ramien ML, Lansang P. Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section I: Overview Of Pediatric Atopic Dermatitis. J Cutan Med Surg. 2019;23(5):3S-11S. https://doi.org/10.1177/1203475419882654.CrossRefPubMed

66.

Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36(3):367–76. https://doi.org/10.1080/03007995.2019.1699516.CrossRefPubMed

67.

Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the atopic dermatitis control tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15. https://doi.org/10.1186/s12895-019-0095-3.CrossRefPubMedPubMedCentral

68.

Vourc’h-Jourdain M, Barbarot S, Taieb A, Diepgen T, Ambonati M, Durosier V, et al. Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. A preliminary feasibility study. Dermatology. 2009;218(3):246–51. https://doi.org/10.1159/000193997.CrossRefPubMed

69.

Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66(8):1114–21. https://doi.org/10.1111/j.1398-9995.2011.02577.x.CrossRefPubMed

70.

Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–9. https://doi.org/10.1001/archderm.140.12.1513.CrossRefPubMed

71.

Yew YW, Zhao X, Apfelbacher CJ. The Patient-Oriented Eczema Measure: estimating the minimal important change in an outpatient clinic cohort. J Eur Acad Dermatol Venereol. 2020;34(6):1273–9. https://doi.org/10.1111/jdv.16122.CrossRefPubMed

72.

Silverberg JI, Lei D, Yousaf M, Singam V, Kantor R, Hsu DY, et al. Comparison of patient-oriented eczema measure and patient-oriented scoring atopic dermatitis vs eczema area and severity index and other measures of atopic dermatitis. A validation study. Ann Allergy Asthma Immunol. 2020;120(5):78–83. https://doi.org/10.1016/j.anai.2020.03.006.CrossRef

73.

Howells LM, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP). Br J Dermatol. 2020;183(3):524–36. https://doi.org/10.1111/bjd.18780.CrossRefPubMedPubMedCentral

74.

Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol. 2014;171(6):1318–25. https://doi.org/10.1111/bjd.13237.CrossRefPubMedPubMedCentral

75.

Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175(1):69–79. https://doi.org/10.1111/bjd.14773.CrossRefPubMed

76.

Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19673.CrossRefPubMedPubMedCentral

77.

Luján-Tangarife J, Cardona-Arias J. Construcción y validación de escalas de medición en salud: revisión de propiedades psicométricas. Arch Med. 2015;11(3):1. https://doi.org/10.3823/1251.CrossRef

78.

Sanclemente-Mesa G, García H, Aguirre-Acevedo D, Jones-Caballero M, Lugo LH, Escobar C, et al. Fiabilidad y validez de constructo de la versión colombiana del instrumento de calidad de vida Skindex-29© en Medellín, Colombia. IATREIA. 2017;30(1):21–33. https://doi.org/10.17533/udea.iatreia.v30n1a02.CrossRef

79.

Hernández-Mantilla N, Cárdenas-Rojas PJ, Picó J, Pareja-Zabala MJ. Dermatitis atópica: tratamiento y costos desde la perspectiva de expertos clínicos colombianos. Dermatol Rev Mex. 2020;64(5):528–34.

80.

Casara C, Eidt L, Cunha V. Prevalence study of dermatoses referred to the phototherapy unit at the Dermatology Service of the Clinics Hospital of Porto Alegre, RS, Brazil. An Bras Dermatol. 2013;88(2):211–5. https://doi.org/10.1590/S0365-05962013000200004.CrossRefPubMedPubMedCentral

81.

Asociación Argentina de Alergia e Inmunología Clínica. Guías para el Diagnóstico y Tratamiento de la Dermatitis Atópica [Guidelines for the Diagnosis and Treatment of Atopic Dermatitis]. 2019. https://alergia.org.ar/pdfs/guias_argentinas_dermatitis_atopica_2019.pdf

82.

Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Resolución No. 2019006204. Por la cual se concede un Registro Sanitario [Resolution No. 2019006204. By which a Sanitary Registry is granted] 2019. http://web.sivicos.gov.co/registros/pdf/15726943_2019006204.pdf.

83.

Comisión Federal para la Protección contra Riesgos Sanitarios de México. 2020. https://www.gob.mx/cofepris.

84.

Agência Nacional de Vigilância Sanitária. Dupixent (dupilumabe): nova indicação [Dupixent(dupilumab): new indications]. 2020. https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/dupixentdupilumabe-nova-indicacao.

85.

Sánchez J, Cardona R. Effect of immunotherapy on basophil activation induced by allergens in patients with atopic dermatitis. Rev Alerg Mex. 2014;61(3):168–77.PubMed

86.

Cardona R, Lopez E, Beltrán J, Sánchez J. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. Allergol Immunopathol (Madr). 2014;42(2):90–5. https://doi.org/10.1016/j.aller.2012.07.005.CrossRef

87.

Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert perspectives on Mmanagement of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519–31. https://doi.org/10.1016/j.jaip.2017.08.005.CrossRefPubMed

88.

Cherrez-Ojeda I, Vanegas E, Felix M, Mata VL, Jiménez FM, Sanchez M, et al. Frequency of use, perceptions and barriers of information and communication technologies among Latin American physicians: an Ecuadorian cross-sectional Study. J Multidis Healthc. 2020;2020(13):259–69. https://doi.org/10.2147/JMDH.S246253.CrossRef

89.

Lee MK, Seo JH, Chu H, Kim H, Jang YH, Jeong JW, et al. Current status of patient education in the management of atopic dermatitis in Korea. Yonsei Med J. 2019;60(7):694–9. https://doi.org/10.3349/ymj.2019.60.7.694.CrossRefPubMedPubMedCentral

90.

Saito-Abe M, Futamura M, Yamamoto-Hanada K, Yang L, Suzuki K, Ohya Y. Topical corticosteroid phobia among caretakers of children with atopic dermatitis: a cross-sectional study using TOPICOP in Japan. Pediatr Dermatol. 2019;36(3):311–6. https://doi.org/10.1111/all.13189.CrossRefPubMed

91.

Gonzales F, Ramdane N, Delebarre-Sauvage C, Modiano P, Duhamel A, Lasek A. Monitoring of topical corticosteroid phobia in a population of parents with children with atopic dermatitis using the TOPICOP® scale: prevalence, risk factors and the impact of therapeutic patient education. J Eur Acad Dermatol Venereol JEADV. 2017;31(3):e172–4. https://doi.org/10.1111/jdv.13961.CrossRefPubMed

92.

Pickett K, Loveman E, Kalita N, Frampton GK, Jones J. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. Health Technol Assess Winch Engl. 2015;19(86):1–176. https://doi.org/10.3310/hta19860.CrossRef

93.

Schmitt J, Csötönyi F, Bauer A, Meurer M. Determinants of treatment goals and satisfaction of patients with atopic eczema. J Dtsch Dermatol Ges. 2008;6(6):458–65. https://doi.org/10.1111/j.1610-0387.2007.06609.x.CrossRefPubMed

94.

Greis C, Meier Zürcher C, Djamei V, Moser A, Lautenschlager S, Navarini AA. Unmet digital health service needs in dermatology patients. J Dermatol Treat. 2018;29(7):643–7. https://doi.org/10.1080/09546634.2018.1441488.CrossRef

95.

Maurer M, Weller K, Magerl M, Maurer RR, Vanegas E, Felix M, et al. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. World Allergy Organ J. 2020. https://doi.org/10.1016/j.waojou.2020.100475.CrossRefPubMedPubMedCentral

96.

Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2020;76(3):816–30. https://doi.org/10.1111/all.14687.CrossRefPubMed

97.

Chan Y-C, Tay Y-K, Sugito T-L, Boediardja SA, Chau D-D, Nguyen K-V, et al. A study on the knowledge, attitudes and practices of Southeast Asian dermatologists in the management of atopic dermatitis. Ann Acad Med Singapore. 2006;35(11):794–803.PubMed

98.

Chérrez Ojeda I, Calderon JC, Mori J, Colombaro D, Braido F, Soria E, et al. Patient-physician relationship in the management of asthma: Multicentric approach in Latin America. J Asthma Off J Assoc Care Asthma. 2016;53(7):751–60. https://doi.org/10.3109/02770903.2016.1145691.CrossRef

99.

van Os-Medendorp H, Deprez E, Maes N, Ryan S, Jackson K, Winders T, et al. The role of the nurse in the care and management of patients with atopic dermatitis. BMC Nurs. 2020;19:102. https://doi.org/10.1186/s12912-020-00494-y.CrossRefPubMedPubMedCentral

Title: The Unmet Needs in Atopic Dermatitis Control in Latin America: A Multidisciplinary Expert Perspective
Authors: Jorge Sanchez
Ivan Cherrez-Ojeda
Cesar Galvan
Elizabeth Garcia
Natalia Hernández-Mantilla
Angela Londoño Garcia
Elizabeth McElwee
Mariana Rico Restrepo
Enrique Rivas
Benjamin Hidalgo
Publication date: 01-10-2021
Publisher: Springer Healthcare
Keyword: Atopic Dermatitis
Published in: Dermatology and Therapy / Issue 5/2021
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-021-00595-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Unmet Needs in Atopic Dermatitis Control in Latin America: A Multidisciplinary Expert Perspective

Abstract

Introduction

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2021

Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older

Patient Journey in Atopic Dermatitis: The Real-World Scenario

Effect of Vitamin-Containing Amino Acid Supplements on Menopausal Symptoms and Age-Related Skin Changes: A Randomised, Double-Blind, Placebo-Controlled Study

Review of the Latest Methods of Epidermolysis Bullosa and Other Chronic Wounds Treatment Including BIOOPA Dressing

A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm

An Economic Analysis of the Impact of Homecare Drug Administration for Biologic Interventions Available for Plaque Psoriasis in the UK

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page